Court: Supreme Court of the United States

After the US Supreme Court overturned the Chevron doctrine on 28 June there are differing opinions on how USPTO rule-making packages will be impacted

01 July 2024

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2024

As courts continue to shape and refine the metes and bounds of PTAB estoppel on subsequent invalidity challenges before the district courts and the USPTO, patent challengers should carefully consider their strategies for invalidating biotechnology and pharmaceutical patents.

24 June 2024

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2024

A slew of recent litigation in the biologics and biosimilars space has drastically changed the landscape of this space and made it more challenging for biopharma companies and IP professionals.

24 June 2024

The Amgen patent enablement ruling was 2023’s crowning gem but the US Supreme Court also issued major trademark decisions and has a host of patent appeals pending

29 December 2023

IAM understands that Chris Coons plans to file legislation to create a presumption that a winning patent holder should get a permanent injunction

03 November 2023

Featured in SEP/FRAND Hub 2023/2024

The lack of any statement from any governmental agencies during 2023 concerning SEP/FRAND policy indicates a more neutral stance by the government in which SEP issues must be governed on a case-by-case basis under controlling law. If there is a change in administration as a result of the 2024 election, US SEP holders will want to closely monitor any changes in SEP policy and their implications.

27 October 2023

Saturday Opinion: Chief IP officers should be acutely aware of this legislation’s profound implications, especially for medical devices, AI, and healthcare

07 October 2023

Given the challenges in the US patent system and world markets, companies must follow comprehensive IP strategies that align IP investment with business goals – and consider the competition

03 October 2023

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2023

Whether the new Inflation Reduction Act will protect and foster the growing biosimilar market remains to be seen, but litigation in the biosimilars space has already transformed the landscape, making it increasingly difficult to navigate for biopharma companies and IP professionals.

25 August 2023

Featured in SEP/FRAND Hub 2022/2023

Both the PREVAIL Act and Patent Eligibility Restoration Act seek to enhance participation in the patent system. However, expanded eligibility and a weaker PTAB will undoubtably raise concerns from both SEP holders and implementers, and it remains to be seen whether these approaches will ultimately benefit or harm the larger market.

24 August 2023